The Role of Indoleamine 2,3-Dioxygenase in Renal Tubular Epithelial Cells Senescence under Anoxia or Reoxygenation

Biomolecules. 2021 Oct 15;11(10):1522. doi: 10.3390/biom11101522.

Abstract

Ischemia-reperfusion injury is the commonest form of acute kidney injury (AKI). Tubular epithelial cell senescence contributes to incomplete recovery from AKI and predisposes to subsequent chronic kidney disease. In cultures of primary proximal renal tubular epithelial cells (RPTECs) subjected to anoxia or reoxygenation, we evaluated the role of indoleamine 2,3-dioxygenase 1 (IDO) in cellular senescence. Proteins of interest were assessed with Western blotting or enzyme-linked immunosorbent assay or histochemically. Under anoxia or reoxygenation, IDO expression and activity were increased. Moreover, the two IDO-derived pathways, the general control nonderepressible 2 kinase (GCN2K) pathway and the aryl-hydrocarbon receptor (AhR) pathway, were also activated. A DNA damage response (DDR) took place and led to increased levels of the cell-cycle inhibitors p21 and p16, and senescence-associated β-galactosidase (SA-β-Gal) activity. Cell proliferation was inhibited, and more IL-6 was produced. The IDO inhibitor 1-DL-methyl-tryptophan ameliorated the DDR; decreased p21, p16, and SA-β-Gal activity; restored cell proliferation; and decreased IL-6 production. The AhR inhibitor CH223191 did not affect the above parameters. In conclusion, anoxia and the subsequent reoxygenation upregulate IDO. IDO depletes tryptophan and activates GCN2K. The latter enhances the anoxia- or reoxygenation-induced DDR, resulting in increased p21 and p16 expression and eventually leading to RPTEC senescence. Since cellular senescence affects AKI outcome, the role of IDO in cellular senescence and the possible therapeutic role of IDO inhibitors deserve further investigation.

Keywords: DNA damage response; acute kidney injury; indoleamine 2,3-dioxygenase; ischemia-reperfusion; p16; p21; senescence.

MeSH terms

  • Acute Kidney Injury / drug therapy
  • Acute Kidney Injury / genetics
  • Acute Kidney Injury / pathology
  • Animals
  • Azo Compounds / pharmacology
  • Cell Proliferation / drug effects
  • Cellular Senescence / genetics*
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics
  • DNA Damage / drug effects
  • Enzyme Inhibitors / pharmacology
  • Epithelial Cells / drug effects
  • Humans
  • Hypoxia / drug therapy
  • Hypoxia / genetics*
  • Hypoxia / pathology
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / antagonists & inhibitors
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / genetics*
  • Interleukin-6 / genetics*
  • Kidney Tubules, Proximal / drug effects
  • Kidney Tubules, Proximal / metabolism
  • Kidney Tubules, Proximal / pathology
  • Mice
  • Oxygen / metabolism
  • Protein Serine-Threonine Kinases / genetics*
  • Pyrazoles / pharmacology
  • Receptors, Aryl Hydrocarbon / antagonists & inhibitors
  • Receptors, Aryl Hydrocarbon / genetics
  • Reperfusion Injury / drug therapy
  • Reperfusion Injury / genetics
  • Reperfusion Injury / pathology
  • Tryptophan / analogs & derivatives*
  • Tryptophan / pharmacology
  • rho GTP-Binding Proteins / genetics

Substances

  • 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide
  • Azo Compounds
  • Cyclin-Dependent Kinase Inhibitor p16
  • Enzyme Inhibitors
  • Indoleamine-Pyrrole 2,3,-Dioxygenase
  • Interleukin-6
  • Pyrazoles
  • Receptors, Aryl Hydrocarbon
  • alpha-methyltryptophan
  • tryptophan methyl ester
  • Tryptophan
  • EIF2AK4 protein, human
  • Protein Serine-Threonine Kinases
  • rho GTP-Binding Proteins
  • Oxygen